Remember when the Democrats took over Congress and promised to do something about prescription drug prices under Part D? They didn't get very far, and they haven't been talking about it since. But when beneficiaries get ready to renew their Part D coverage in 2009-and see how much their costs are going up-there may be a lot more to talk about.
Michael McCaughan
On November 15, more than 17 million Medicare beneficiaries enrolled in stand-alone Medicare Part D plans will have the chance...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
European health systems already pay far too much for new medicines and payers will not accept higher prices to compensate for lower US prices, according to Anja Schiel, from NOMA, the Norwegian health technology assessment body.
The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.
The UK drug regulator, the MHRA, is set to launch its decentralized manufacturing framework in July, and has issued a series of guidance documents that it believes will help companies and also be of value to other countries that are considering how best to regulate the fledging sector.
Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.
The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.
